Cilostazol Reduces Restenosis Following Endovascular Therapy in Patients with Femoro-popliteal Lesions

Cilostazol Reduces Restenosis Following Endovascular Therapy in Patients with Femoro-popliteal Lesions - Cilostudy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001036

Enrollment

127

Registered

2008-04-01

Start date

2004-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who underwent endovascular therapy for symptomatic de novo FP lesions

Interventions

Aspirine 100mg/day, Cilostazol (200mg/day) Aspirine 100mg/day, Ticlopidine (200mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) de novo FP lesions of > 50 percent diameter stenosis, occlusion without inflow lesions (the aorto-Iliac or common femoral artery) and with outflow lesions of the below-the-knee arteries better than one vessel run off as evaluated by angiography 2) patients with symptomatic PAD with claudication (Fontaine 2), intractable rest pain (Fonatine 3) and non- healing ulcer (Fontaine 4) due to FP lesions

Exclusion criteria

Exclusion criteria: acute onset critical limb ischemia, previous bypass surgery or angioplasty for the FP lesions, presence of untreated pelvic lesions, and known intolerance to the medication or contrast agents

Design outcomes

Primary

Measure	Time frame
patency	—

Secondary

Measure	Time frame
1) Target lesion revascularization 2) All events included restenosis, amputation and death from any causes	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026